/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Plus Therapeutics Inc Share Price Today: Live Updates & Key Insights

Plus Therapeutics Inc share price today is $0.2446, up -4.22%. The stock opened at $0.3074 against the previous close of $0.3077, with an intraday high of $0.327 and low of $0.2931.

Plus Therapeutics Inc Share Price Chart

style
pb-0

Plus Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Plus Therapeutics Inc Share Price Performance

$0.2446 -0.0422(-4.22%) PSTV at 13 Mar 2026 02:53 PM Biotechnology
Lowest Today 0.2931
Highest Today 0.327
Today’s Open 0.3074
Prev. Close 0.3077
52 Week High 2.08
52 Week Low 0.16
Day’s Range: Low 0.2931 High 0.327
52-Week Range: Low 0.16 High 2.08
1 day return -
1 Week return +2.51
1 month return +7.95
3 month return -52.25
6 month return -27.97
1 year return -62.16
3 year return -93.22
5 year return -99.33
10 year return -

Plus Therapeutics Inc Institutional Holdings

Vanguard Group Inc 1.28

L1 Global Manager Pty Ltd 1.28

Vanguard Institutional Extnd Mkt Idx Tr 0.85

Altium Capital Management, LP 0.52

Geode Capital Management, LLC 0.46

Fidelity Extended Market Index 0.41

UBS Group AG 0.35

BlackRock Inc 0.26

Blackrock Extended Mkt Fund CF 0.26

Extended Equity Market Fund K 0.22

State Street Corp 0.19

Northern Trust Corp 0.15

Fidelity Total Market Index 0.14

Fidelity Series Total Market Index 0.11

NT Ext Equity Mkt Idx Fd - L 0.09

Scientech Research LLC 0.08

Spartan Extended Market Index Pool F 0.08

NT Ext Equity Mkt Idx Fd - NL 0.07

Abante Quant Value FI 0.06

Spartan Total Market Index Pool G 0.06

Northern Trust Extended Eq Market Idx 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Susquehanna International Group, LLP 0.04

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.04

Vanguard U.S. Eq Idx £ Acc 0.03

Extended Equity Market Fund M 0.03

Mercer Global Advisors Inc. 0.02

Dagco Inc 0.01

Kestra Advisory Services, LLC 0.01

Cubist Systematic Strategies, LLC 0.01

TWO SIGMA SECURITIES, LLC 0.01

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.01

NT US Market Cap Idx Fd - L 0.00

Tower Research Capital LLC 0.00

JHVIT Total Stock Market Index I 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

SBI Securities Co Ltd 0.00

Bank of America Corp 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Advisor Group Holdings, Inc. 0.00

Plus Therapeutics Inc Market Status

Strong Buy: 1

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Plus Therapeutics Inc Fundamentals

Market Cap 54.88 M

PB Ratio 10.8597

PE Ratio 0.0

Enterprise Value 38.30 M

Total Assets 6.63 M

Volume 5470871

Plus Therapeutics Inc Company Financials

Annual Revenue FY23:224000 0.2M, FY22:224000 0.2M, FY21:0 0.0M, FY20:303000 0.3M, FY19:6998000 7.0M

Annual Profit FY23:null 0.0M, FY22:224000 0.2M, FY21:-66000 -0.1M, FY20:303000 0.3M, FY19:6998000 7.0M

Annual Net worth FY23:-15164000 -15.2M, FY22:-20838000 -20.8M, FY21:-14331000 -14.3M, FY20:-9348000 -9.3M, FY19:-12742000 -12.7M

Quarterly Revenue Q3/2025:1397000 1.4M, Q2/2025:1390000 1.4M, Q1/2025:1059000 1.1M, Q3/2024:0 0.0M, Q2/2024:1279000 1.3M

Quarterly Profit Q3/2025:1311000 1.3M, Q2/2025:1304000 1.3M, Q1/2025:878000 0.9M, Q3/2024:null 0.0M, Q2/2024:-1494000 -1.5M

Quarterly Net worth Q3/2025:-4423000 -4.4M, Q2/2025:5151000 5.2M, Q1/2025:-17401000 -17.4M, Q3/2024:-2874000 -2.9M, Q2/2024:-2940000 -2.9M

About Plus Therapeutics Inc & investment objective

Company Information Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Organisation Biotechnology

Employees 21

Industry Biotechnology

CEO Dr. Marc H. Hedrick M.B.A., M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow